Drug Trial Radar · NCT07911514
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 9, 2026
Primary completion
May 4, 2027
Study completion May 4, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Quotient Sciences
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will randomize 60 healthy men and women aged 18-55 years living with overweight/obesity.
Conditions
- Healthy Participants
Interventions
AZD9550 solution for injectionDrug
AZD9550 solution for injection will be administered as a single SC injection
AZD6234 solution for injectionDrug
AZD6234 solution for injection will be administered as a single SC injection
Formulation 1 solution for injectionDrug
Formulation 1 solution for injection will be administered as a single SC injection
Formulation 2 solution for injectionDrug
Formulation 2 solution for injection will be administered as a single SC injection
Formulation 3 solution for injectionDrug
Formulation 3 solution for injection will be administered as a single SC injection
Formulation 4 solution for injectionDrug
Formulation 4 solution for injection will be administered as a single SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Plasma sample collection from pre dose to Day 22
- Area under the curve from time 0 to the time of last quantifiable concentration (AUClast)Time frame: Plasma sample collection from pre dose to Day 22
- Area under the curve from time 0 extrapolated to infinity (AUCinf)Time frame: Plasma sample collection from pre dose to Day 22
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Ruddington, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.